CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative hosted a Clinical Trial Workshop in Hong Kong December 8-9th 2018. Formed in 2015, CommNETs operates within the auspices of the Canadian Cancer Trials Group and the Australasian Gastro-intestinal Trials Group to bring together researchers, clinicians, and consumers from Australia, New Zealand and Canada to improve the outcomes of patients with Neuroendocrine Tumours (NETs).
The Pharmacist Network is actively seeking volunteers as Pharmacist Representatives for the Breast and Gastrointestinal Disease Site Committees. Participation in these opportunities earns volunteers a fully funded invitation to the annual CCTG Spring Meeting in Toronto.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at:
At a press conference last week CCTG announced a new clinical trial, opening across Canada. IND.234 is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world. The IND.234 clinical trial, uses liquid biopsy technology to screen for genomic markers in prostate cancer patients.
When it comes to cancer, a lot can happen in 30 minutes. Someone can have a life-changing appointment with their doctor, receive a supportive phone call from a peer or start cancer treatment.
The MA37 (BIG 14-03) PALLAS Study "PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer" was closed to accrual as of November 30, 2018.
We are coming up to a big holiday for American families. Please expect closure of U.S. Operations offices and laboratories on Thursday, November 22nd for the U.S. Thanksgiving. If you are planning to ship specimens to the U.S., please plan accordingly.
A video interview with Dr. Anna Spreafico who is the CCTG study chair for the HN.9 clinical trial.
https://youtu.be/0zfM1ghcwnM
